Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{186369,
        author = {pradnya pehere and Dr Sushila Kaura},
        title = {Review on Role of Nanotechnology in the Management of Brain Disorders},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {6},
        pages = {862-873},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=186369},
        abstract = {Brain disorders such as Alzheimer’s disease, Parkinson’s disease, and brain tumors remain difficult to treat due to the complex structure of the central nervous system and the restrictive blood–brain barrier (BBB). Nanotechnology offers innovative strategies to overcome these challenges by enabling targeted and controlled drug delivery to the brain. Nanocarriers like liposomes, polymeric nanoparticles, dendrimers, and metallic nanoparticles improve drug stability, enhance BBB permeability, and minimize systemic toxicity. Surface modification of nanoparticles with ligands or antibodies allows site-specific delivery and sustained therapeutic action. In addition to therapy, nanotechnology contributes to early diagnosis through nanosensors and imaging agents, enabling real-time monitoring of disease progression. Thus, nanotechnology holds immense potential in advancing both the diagnosis and treatment of brain disorders, providing new avenues for effective and personalized neurotherapeutic interventions.},
        keywords = {Alzheimer’s disease, Parkinson’s disease, liposomes, polymeric nanoparticles.},
        month = {November},
        }